Individual results/experiences may vary. He is an expert when it comes to a challenging type of lung cancer. It's called ROS1+ non-small cell lung cancer (NSCLC), and it's known for being aggressive ...

positive lung cancer (ROS1)-positive NSCLC According to research, about 50% to 60% of people with EGFR- or ALK-positive lung cancer go on to develop brain mets. Why is this? Doctors aren’t sure.

and a favorable safety profile with low incidence of neurologic adverse events in TKI-naive and TKI-pretreated patients with ROS1+ non-small cell lung cancer (NSCLC). These results were presented ...

has been cleared for patients with ROS1-positive non-small-cell lung cancer (NSCLC) on the back of overall response rate (ORR) data from the phase 1/2 TRIDENT-1 study after a priority review by ...

The NSCLC must not have EGFR, ALK, or ROS1 mutations ... trials that looked at how well it worked to treat the cancer. In the EMPOWER-Lung 1 clinical trial, people received either Libtayo ...

The test looks for DNA from dead tumor cells present in the bloodstream to determine whether the cancer cells have mutations in specific genes (including EGFR, ALK, ROS1, RET, and BRAF).

“Taletrectinib is a highly selective, next-generation oral tyrosine kinase inhibitor, with the potential to expand what’s possible for patients with ROS1-positive non-small cell lung cancer ...

“The specialist said, ‘Well, I’m really sorry to tell you Ros, you have stage four lung cancer, and it’s metastasised to your brain’,” she told the ABC last month. “And (my son and ...

Priority Review designation underscores the significant advancement taletrectinib may offer patients with ROS1+ NSCLC, for which there remains a high unmet need for new treatment options.